arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Celularity Inc

CELU
$0.74 ▼ -0.06 (-7.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Celularity Inc faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $21.6M
Dividend Yield —
Revenue Growth -5.3% ↗
Op. Margin -78.0% ↗
ROIC 9.4% ↘
FCF / Share $-0.04 ↘
Trailing P/E 37.0x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.43M
↓ -5.3% —
Net Income Profit after all expenses
$874.00K
— 0.0% —
Operating Margin Operating profit as % of sales
-78.0%
↑ +70.4% 0th
FCF / Share Free cash flow per share
$-0.04
↓ -176.2% —
Long-Term Debt Long-term obligations
$17.03M
↑ +258.8% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns ↑
100
Financial Health ↑
22
Cash Quality ↓
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 32 quarters